Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about new clinical data from its phase two melanoma study, known as the SCOPE trial, featuring its lead ImmunoBody candidate, iSCIB1+. L’Huillier highlighted that the trial has achieved the objectives set out for it, confirming the parameters for the company’s upcoming registrational phase three study. The findings now provide clarity on dosing, patient population, and trial design. “Our SCOPE study…has met the objectives that we set out for it,” he said. A key point of the discussion focused on the data, which showed a 74% progression-free survival rate at 16 months for iSCIB1+. This compares to 46% at 12 months for the standard of care, which typically includes dual checkpoint inhibitors Ipilimumab and Nivolumab. L’Huillier noted this as a "really strong and durable benefit" on top of existing treatments. He also addressed how iSCIB1+ performed across patient subgroups where existing therapies are typically less effective—such as BRAF, PD-L1 status, and those with prior checkpoint treatment—with results showing clinically meaningful benefit across all. Scancell now plans to begin its phase three trial in late 2026, having received supportive regulatory feedback. L’Huillier also said the data has materially strengthened the company’s case for partnering and financing opportunities as part of a dual-track strategy to either partner or proceed independently. Watch the full video for more insights. Like, subscribe, and enable notifications so you never miss an update from Proactive’s YouTube channel. #Scancell #Melanoma #CancerResearch #ClinicalTrials #Immunotherapy #iSCIB1 #BiotechNews #Phase3Trial #Oncology #ProactiveInvestors
